Centrus Energy Corp vs 22nd Century Group Inc — how do they compare? Centrus Energy Corp trades at $164.95 (market cap $3.08B), while 22nd Century Group Inc trades at $4.25 (market cap $1.49M). The key difference: Centrus Energy Corp is far larger — about 2067.1× 22nd Century Group Inc's market cap. Which is the better fit depends on your goals.
| LEU | XXII | |
|---|---|---|
Market Cap | $3.08B | $1.49M |
Sector | Energy | Technology |
52-Week High | $436.00 | $1.07K |
52-Week Low | $146.61 | $3.90 |
Enterprise Value | $2.39B | -$6.74M |
Signals from Pluang's Aura AI — not financial advice
Centrus Energy (LEU) trades at $156.39, showing modest daily gains amid a bearish technical outlook. The company reported mixed quarterly earnings, with a recent beat in Q1 2026 but misses in prior quarters. Positive developments include a $1 billion+ DOE contract and inclusion in the S&P SmallCap 600, highlighting its strategic role in the U.S. nuclear fuel supply chain. Valuation ratios remain elevated, with a P/E of 56.75, while profitability metrics like a 13.4% net income margin reflect solid operational performance.
The outlook for LEU is cautiously optimistic, driven by government contracts and nuclear energy tailwinds, but high valuation and recent earnings volatility pose risks. Analyst consensus is mixed with a $223.14 price target, suggesting potential upside if execution improves. Key risks include dependency on federal contracts and competitive pressures in the uranium sector.
XXII trades at $4.32, down 0.23% with bearish technical signals. The company shows negative profitability with -65.76% net income margin and -130.19% ROE, though valuation ratios appear low with P/S of 0.03. Recent corporate actions include a 20:1 reverse stock split in June 2026. The company is expanding VLN product distribution in key markets including California and New York, supported by positive FDA regulatory developments.
While analyst consensus is 75% buy-rated, fundamental challenges persist with consistent revenue declines and negative cash flow from operations. Investment opportunity lies in successful VLN brand expansion and regulatory approvals, but risks include ongoing losses, competitive tobacco market pressures, and execution uncertainty in scaling reduced-nicotine products.
Trailing returns across standard periods
Latest headlines on both assets
Centrus Energy is a leading supplier of nuclear fuel and services for the global power industry. It specializes in supplying low-enriched uranium and developing next-generation fuels for advanced nuclear reactors.
Read more on LEU →22nd Century Group is a plant biotechnology company that uses genetic engineering and gene editing to control the levels of nicotine in tobacco plants. Its flagship product line, VLN®, is the first and only combustible cigarette authorized by the FDA as a Modified Risk Tobacco Product (MRTP), containing 95% less nicotine than traditional cigarettes to help adult smokers smoke less.
Read more on XXII →